n the last 25 years, the Positive and Negative Syndrome Scale (PANSS) has been largely used to assess schizophrenia symptom intensity, but little information is available on how this scale was generally applied when evaluating the ef fi cacy of schizophrenia therapies in randomized clinical trials. In the attempt to address this topic, a systematic PubMed Search was carried out using the keywords “ PANSS ” and “ Randomized Clinical Trials ” . The analysis of retrieved articles highlighted that PANSS has constituted a suitable psychometric instru- ment to investigate the ef fi cacy of pharmacological and non-pharmacological therapies. However, the informa- tion potentially provided by this scale was only partially reported in research articles, when characterizing the symptomatic features of patients at baseline. Furthermore, a consensus is needed to identify methodological strategies that may properly adapt PANSS-subscale structure with the symptomatic pro fi les of individuals en- rolledinrandomizedcontrolled trials.The possibility that PANSSinterviewprocedures and enrollmenteligibility criteria may in fl uence the symptomatic composition of patients involved in these studies is also discussed.
On the use of the Positive and Negative Syndrome Scale in randomized clinical trials
NICOTRA, ERALDO FRANCESCO;
2015-01-01
Abstract
n the last 25 years, the Positive and Negative Syndrome Scale (PANSS) has been largely used to assess schizophrenia symptom intensity, but little information is available on how this scale was generally applied when evaluating the ef fi cacy of schizophrenia therapies in randomized clinical trials. In the attempt to address this topic, a systematic PubMed Search was carried out using the keywords “ PANSS ” and “ Randomized Clinical Trials ” . The analysis of retrieved articles highlighted that PANSS has constituted a suitable psychometric instru- ment to investigate the ef fi cacy of pharmacological and non-pharmacological therapies. However, the informa- tion potentially provided by this scale was only partially reported in research articles, when characterizing the symptomatic features of patients at baseline. Furthermore, a consensus is needed to identify methodological strategies that may properly adapt PANSS-subscale structure with the symptomatic pro fi les of individuals en- rolledinrandomizedcontrolled trials.The possibility that PANSSinterviewprocedures and enrollmenteligibility criteria may in fl uence the symptomatic composition of patients involved in these studies is also discussed.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
